Lundbeck Lu AF82422 Multiple System Atrophy 2024

Lundbeck presents Lu AF82422, an anti-α-synuclein compound with potential to become the first disease-modifying therapy for Multiple System Atrophy (MSA), a rare progressive neurodegenerative disorder. The presentation covers Phase II proof-of-concept data from a January 2024 investor conference call, addressing an orphan disease with limited current treatment options beyond symptomatic care.